CompletedPhase 1NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Maryam FouladiCOG Phase I Consortium
- Intervention
- Akt inhibitor MK2206(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2011
Study locations (25)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Childrens Hospital of Orange County, Orange, California, United States
- University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Indiana University Medical Center, Indianapolis, Indiana, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University Medical Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01231919 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics